Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phas
about
Prophylactic Measures During Induction for Acute Myeloid Leukemia.A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored VaccinesImmunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine DesignRespiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection.Latest options for treatment of bronchiolitis in infants.Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.Strategies to develop vaccines of pediatric interest.Ongoing developments in RSV prophylaxis: a clinician's analysis.Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.In silico analysis of amino acid variation in human respiratory syncytial virus: insights into immunodiagnosticsDevelopment of novel vaccine vectors: Chimpanzee adenoviral vectors.Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.Simian adenoviruses as vaccine vectors.New Vaccine Technologies to Combat Outbreak Situations
P2860
Q30235496-B69B1FCF-DA44-4B61-936D-F69A12FB3D58Q33724960-8452506C-1B98-4371-A0D0-3A348774E61FQ35928588-22351F1B-9E7F-4E9E-BC7B-CC899D71B03FQ37729137-4DA20817-85F0-43BB-A450-28D581B6CF32Q38637248-8DBB4E68-9894-4B5A-AC80-6D86F889C935Q38744226-9D99170E-214B-42A0-8108-553187542049Q38803541-4E6E60B5-05DC-42D1-9111-D1BDC1D37CA1Q38819027-258ACF5B-5183-404C-BB8E-B10B02C46EF9Q39303791-364B9C80-D6B3-43B5-B928-9D76C351D1BCQ40065136-BE3072A1-D0F5-4B6A-989F-F9A90ED32B00Q41653256-BC4FEB18-C2AA-4F2D-8ABB-D44A8CFA0D5CQ47558190-075C6435-400F-4732-A5D2-1948DC7B6FFAQ47558367-5418142E-06D1-4084-9367-1E84EAD651A5Q54531277-C8A88E35-4A69-49C9-AB62-454ACE3DBC2DQ57072744-9AB37ECA-3C9D-49BE-8F8C-7A8A404637B0
P2860
Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phas
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Safety and immunogenicity of n ...... scalation, single-centre, phas
@ast
Safety and immunogenicity of n ...... scalation, single-centre, phas
@en
type
label
Safety and immunogenicity of n ...... scalation, single-centre, phas
@ast
Safety and immunogenicity of n ...... scalation, single-centre, phas
@en
prefLabel
Safety and immunogenicity of n ...... scalation, single-centre, phas
@ast
Safety and immunogenicity of n ...... scalation, single-centre, phas
@en
P2093
P2860
P1433
P1476
Safety and immunogenicity of n ...... inical trial in healthy adults
@en
P2093
A J Pollard
A J Thompson
Catherine de Lara
E Scarselli
P Klenerman
P2860
P304
P356
10.1136/BMJOPEN-2015-008748
P577
2015-10-28T00:00:00Z